Close Menu

Fast Track Diagnostics Enteric Fever Kit

Oct 09, 2017

Fast Track Diagnostics has launched a kit to detect the pathogens that cause enteric fever, also known as typhoid or paratyphoid fever. The FTlyo Enteric fever kit includes blood collection tubes containing a proprietary Salmonella enrichment broth, ready-to-use multiplex PCR for detection of Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi, and an internal control. The reagents required for the PCR are lyophilized in single-patient sample tubes that can be stored at room temperature, and clinicians need only add extracted nucleic acids to begin the eight-hour detection workflow.

More Like This

Oct 29, 2020

GenomOncology IgniteIQ

GenomOncology has introduced IgniteIQ, software that extracts and adds computable structure to "clinically relevant" data from PDF next-generation sequencing and pathology reports. The company backs the automated extraction with human review to validate the discrete data elements so the extracted information is useful for clinicians, bioinformaticians, and researchers. IgniteIQ can process PDF documents from both electronic medical records and research data warehouses.    

Oct 29, 2020

Qiagen QiaSeq Human Exome TR Insights

Qiagen has introduced QiaSeq Human Exome TR Insights, a whole-exome sequencing workflow that combines chemistry and informatics to enable researchers to sequence and analyze genomic variations across the entire human exome. The workflow comprises three components: the QiaSeq Human Exome Panel; Qiagen CLC Genomics Workbench NGS data-analysis and -visualization software; and QCI Interpret Translational, new software the enables evidence-based variant annotation, filtering, and interpretation. The QCI Interpret Translational component is powered by the Qiagen Knowledge Base of roughly 2 million unique variants expertly selected from more than 300,000 scientific articles. The exome panel component features a hybrid-capture chemistry and workflow that minimizes GC-induced bias and improves capture efficiency and specificity. Balanced coverage across difficult target regions ensures minimal dropouts and false negatives, Qiagen said.

Oct 29, 2020

Allelica Coronary Artery Disease Risk Calculator

Allelica has launched a cloud-based tool to enable clinical labs and healthcare providers to calculate an individual's lifetime risk of developing coronary artery disease based on the integration of genetic and traditional risk factors. Built on a secure GDPR- and HIPAA-compliant platform, the technology integrates a newly developed genome-wide polygenic risk score (PRS) for CAD into the pooled cohort equation model. It allows physicians to provide patients with highly customizable visual representations of their risk levels compared to the general population. Users can modify risk factors, like decreases in LDL cholesterol, to show patients how manageable lifestyle changes can actively lower their lifetime risk of heart disease. The calculator was developed and validated using UK Biobank data resources and is the latest addition to Allelica's cloud-based PRS pipeline.

Oct 23, 2020

Fabric Genomics Fabric GEM Algorithm for Genetic Disease Diagnosis

Fabric Genomics has launched Fabric GEM, an algorithm designed to identify the likely genetic cause of rare diseases from next-generation sequencing data. Fabric GEM, the latest product in the Fabric Enterprise software suite, uses artificial intelligence to analyze sequencing data (including complex structural variants) and patient clinical information in order to perform probabilistic disease matching and speed genetic diagnoses. The algorithm was developed in collaboration with Mark Yandell of the University of Utah and Stephen Kingsmore of Rady Children's Institute for Genomic Medicine, Fabric said.

Oct 22, 2020

Bionano Genomics Access v1.6, Solve v3.6

Bionano Genomics has updated its suite of data analysis and visualization software tools for its Saphyr genome mapping platform. The new version of Bionano Access is designed to simplify and accelerate every step in the data-analysis workflow, enabling clinical labs to develop tests on the Saphyr more easily. It builds on the Bionano EnFocus FSHD Analysis tools for the automated analysis of variants in a form of muscular dystrophy to allow for similar automated variant analysis for EnFocus panels for other genetic conditions. These include autism spectrum disorder, developmental delay, and repeat expansion disorders, as well as hematologic malignancies and solid tumors. The new version also enables Bionano EnFocus FSHD data to be analyzed on a PC rather than in the cloud or on a compute cluster. In addition, it reduces the time and increases capacity for analyses run on Bionano's cloud-based platform.

Oct 22, 2020

Lexogen Luthor 3' mRNA-seq Library Prep Kit

Lexogen has launched the Luthor 3' mRNA-seq library prep kit for ultra-low input and single-cell sequencing. At sequencing depth of 1 million reads, the kit allows detection of up to 15,000 genes from one cell and up to 13,000 genes from 10 picograms of purified RNA input. Using T7 high-resolution original RNA (THOR) amplification, the kit amplifies RNA directly, without a cDNA intermediate.

Oct 21, 2020

Qiagen QiaPrep&Amp Viral RNA UM Kit

Qiagen has launched the QiaPrep&Amp Viral RNA UM Kit to simplify and accelerate PCR analysis in epidemiological studies of RNA viruses, including SARS-CoV-2. The new kit combines a two-minute, liquid-based sample preparation step with real-time PCR detection in a workflow that can be automated with standard lab equipment for any throughput, assay, and reaction need for both single-plex and multiplex testing. Qiagen said the workflow comprises taking an aliquot from a nasopharyngeal, oropharyngeal, or nasal swab in transport media; adding the aliquot to a buffer optimized for viral RNA template preparation without degradation; and combining this mixture with RT-qPCR reaction mix for subsequent real-time PCR on any thermal cycler using any assay. The entire workflow takes less than an hour compared to about three hours for standard extraction-based qPCR processes, and can be used to process up to 2,600 samples per eight-hour shift per thermal cycler, the company said.

Oct 20, 2020

Genome Diagnostics NGSgo-MX11-3 Multiplexing for HLA Typing

Genome Diagnostics has launched NGSgo-MX11-3, its latest addition to a series of singleplex and multiplex amplification strategies for HLA typing by NGS. NGSgo-MX11-3 consists of amplification primers for eleven HLA genes — HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, DRB3/4/5, DQA1, and DPA-1 — in three mixes per sample. The three-tube design results in low noise levels and well-balanced alleles, making the data quality of the 11-loci multiplex similar to a singleplex strategy, Genome Diagnostics said. NGSgo-MX11-3 is available on a research-use-only basis. The firm anticipates that it will become available as a CE-marked IVD.

Oct 19, 2020

Reaction Biology/4HF Biotec Cell-Based Bioinformatics Service

Drug-discovery CRO Reaction Biology and informatics company 4HF Biotec have introduced a cell-based bioinformatics service that combines Reaction's ProLiFiler cell assay service with 4HF Biotec's Biomarker Analysis and MA Finder informatics tools to help inform drug discovery. Biomarker Analysis searches for mutations, gene copy numbers, and gene expression data, while MoA Finder scans test results to pinpoint modes of action in experimental drug compounds. The service, aimed at the oncology market, will be run at Reaction Biology's lab in Freiburg, Germany.

Oct 16, 2020

IDbyDNA/Illumina RUO Respiratory Pathogen ID/AMR Target Enrichment Panel

IDbyDNA and Illumina this week launched their codeveloped Respiratory Pathogen ID/AMR Target Enrichment Panel for research use only. Developed under a previously announced strategic partnership between the companies, the panel uses IDbyDNA's Explify software platform and Illumina's next-generation sequencing technology to detect more than 280 respiratory pathogens (bacterial, viral, and fungal) as well as genes associated with more than 1,200 antimicrobial resistance markers. Using Illumina's MiniSeq Rapid Reagent Kit, the panel can deliver results in less than 24 hours. IDbyDNA's Explify database includes millions of curated DNA and RNA reference sequences and can identify more than 50,000 microorganisms and more than 6,000 known common and rare pathogens, including antimicrobial resistance.

Oct 14, 2020

Caris Life Sciences CODEai

Caris Life Sciences has launched CODEai (Comprehensive Oncology Data Explorer), a real-world clinico-genomic data platform that uses artificial intelligence technology to integrate the company's catalog of molecular data with cancer treatment information and clinical outcomes data for more than 215,000 patients covering more than 1 million data points per patient.

Integrating genomically profiled patient cases with associated treatments and outcomes, CODEai allows for customized cohort analysis based on a variety of search queries including molecular profiling results, demographic data, diagnostic data, and treatment and survival data. The system also provides data visualization and advanced predictive analytics. The platform is available to members of the Caris Precision Oncology Alliance, a growing collaborative network of cancer centers, as well as to biopharma companies through collaborative relationships. 

Oct 14, 2020

GenomOncology Pathology Workbench

GenomOncology has released a new version of GenomOncology (GO) Pathology Workbench, which the software company said has been updated to process Illumina's TruSight Oncology (TSO) 500 assay and other larger panels. GO Pathology Workbench now can process samples in parallel, cutting sample annotation time by 80 percent. The new release also adds management of higher sample throughput as well as intepretation of copy numbers and structural variants in next-generation sequencing. It draws from datasets not included in previous releases of Pathology Workbench, including gnomAD, MutationTaster, PolyPhen, SIFT, cancerhotspots.org, and the Cancer Gene Census.

Oct 14, 2020

Paragon Genomics CleanPlex ARS-CoV-2-Related NGS Assays

Paragon Genomics has launched four new coronavirus-related CleanPlex next generation sequencing (NGS) assays. The new panels widen the capabilities of the firm's CleanPlex SARS-CoV-2 Research and Surveillance Panel, which allows researchers to sequence the SARS-CoV-2 genome and obtain accurate nucleic acid-level information on the virus for strain typing, mutation monitoring, and other epidemiological studies.

Paragon's CleanPlex ACE2 & TMPRSS2 Panel identifies genetic mutations in patients that are related to disease susceptibility and severity. The test targets genes affecting the binding affinity and expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine rotease 2 (TMPRSS2). The panel interrogates the entire coding region of ACE2 and TMPRSS2, along with more than 70 curated unique quantitative trait loci that regulate their expression. Paragon noted the panel uses CleanPlex technology's three-hour workflow to produce enriched NGS libraries for all major sequencing platforms.

Paragon's CleanPlex SARS-CoV-2 FLEX Research Panel anticipates increases in SARS-CoV-2 viral mutations and offers extra assurance that mutation detection and genome coverage remain optimal. The FLEX panel specifically focuses on variant analysis and tracking of mutations over time. The test also includes degenerate primers and human RNA primer controls for more confident negative sample calling, especially when viral copies are not present or are at extremely low counts, the firm said.

The company also launched its plated 384 Unique Dual-Indexed PCR Primers for Illumina sequencing of its CleanPlex SARS-CoV-2 NGS panels. The primers will allow additional multiplexing capability so that researchers can simultaneously run up to 3,072 CleanPlex sequencing samples on Illumina NovaSeq instruments.

In anticipation of the upcoming flu season, Paragon is also releasing an early-access edition of the CleanPlex Respiratory Research Panel, which combines assays for SARS-CoV-2, influenza A subtypes H1N1, H1N2, H3N2, and influenza B. The combination panel allows for simultaneous influenza detection with SARS-CoV-2 detection or whole-genome sequencing. The extra sensitivity and additional coverage of the multiplex PCR-based method also works for high-throughput sample pooling and screening strategies, the firm said. Paragon expects to expand the panel to include respiratory syncytial virus and possibly other respiratory viruses in the future.

Oct 13, 2020

Purigen Biosystems Ionic Cells to Pure DNA Low Input Kit

Purigen Biosystems has launched its Ionic Cells to Pure DNA Low Input kit for DNA extraction and purification prior to next-generation sequencing or qPCR.

The automated workflow takes one hour and provides consistent yields for as many as 10,00 cultured or sorted cells and as few as 10. According to Purigen, the kit delivers a higher proportion of DNA longer than 20 kb than column-based products. The kit includes six fluidic chips  for use on its benchtop Ionic Purification system and the necessary reagents to process 48 samples.

Oct 12, 2020

Exact Sciences Oncotype MAP Pan-Cancer Tissue Test

Exact Sciences has introduced the Oncotype MAP Pan-Cancer Tissue rapid, comprehensive tumor profiling panel test for patients with advanced, metastatic, refractory, or recurrent cancer. Oncotype MAP provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, including tumor mutations, copy number variants, fusions, tumor mutation burden, microsatellite instability, and protein expression, allowing physicians to understand a patient's tumor profile and effectively recommend targeted therapies or clinical trials, the company said.

The test, which Exact acquired as part of its merger deal with Paradigm Diagnostics in February, was previously called PCDx. 

Oncotype MAP has a turnaround time of three to five business days to guide timely treatment decisions, a sample requirement of as little as 3 mm of tissue or 2-3 slides, and accurate and comprehensive results based on next generation sequencing and immunohistochemistry. Exact also noted that patients who used a previous generation of the test had a 43 percent rate of progression-free survival compared to 5 percent for patients who did not utilize the test.

The Oncotype MAP test report is based on NCCN Compendium-based recommendations, along with potential evidence-based therapies and clinical trials. The report is currently tailored to support clinical decision-making by showing actionable biomarkers associated with more than 100 evidence-based therapies, more than 45 combination therapies, and more than 650 active clinical trial associations, Exact added.

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

NPR reports that some insect pests are now becoming resistant to Bt crops.

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

Nov
18
Sponsored by
Genomenon

Rapid whole-genome sequencing (rWGS) is an emerging method that can provide molecular diagnosis in time to alter acute medical or surgical management and improve outcomes in acutely ill children.